Naltrexone is a medication that is FDA-approved for the treatment of alcohol use disorder (AUD) and opioid use disorder. It is an opioid antagonist that works by blocking the euphoric effects of alcohol, which can lead to decreased craving.\u00a0 The drug is largely underprescribed, despite being shown to be a safe, non-addictive, cost-effective option for those looking to cut back or abstain from drinking alcohol.<\/p>\n
A recent scientific review confirmed the safety of oral naltrexone when used as indicated. British researchers at the University of Manchester found no serious side effects for those who took naltrexone, compared to those who took a placebo.<\/p>\n
“Though naltrexone is licensed for the treatment of alcohol addiction, it remains underutilized,\u201d said lead author Monica Bolton, Ph.D. “And that has devastating consequences for individuals, health and social services in the UK and around the world\u2026It is cost effective and could reduce deaths.”<\/p>\n
Published in the journal BMC Medicine<\/em> the meta-analysis<\/a> of 89 randomized controlled trials, involving over 11,000 people, found naltrexone safe to use.<\/p>\n
<\/p>\n","protected":false},"excerpt":{"rendered":"
Naltrexone is a medication that is FDA-approved for the treatment of alcohol use disorder (AUD) and opioid use disorder. It is an opioid antagonist that works by blocking the euphoric effects of alcohol, which can lead to decreased craving.\u00a0 The … Continued<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_links_to":"","_links_to_target":""},"categories":[17],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/pgdf.org\/wp-json\/wp\/v2\/posts\/3196"}],"collection":[{"href":"https:\/\/pgdf.org\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pgdf.org\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pgdf.org\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pgdf.org\/wp-json\/wp\/v2\/comments?post=3196"}],"version-history":[{"count":2,"href":"https:\/\/pgdf.org\/wp-json\/wp\/v2\/posts\/3196\/revisions"}],"predecessor-version":[{"id":3234,"href":"https:\/\/pgdf.org\/wp-json\/wp\/v2\/posts\/3196\/revisions\/3234"}],"wp:attachment":[{"href":"https:\/\/pgdf.org\/wp-json\/wp\/v2\/media?parent=3196"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pgdf.org\/wp-json\/wp\/v2\/categories?post=3196"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pgdf.org\/wp-json\/wp\/v2\/tags?post=3196"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}